Antibody-mediated rejection (AMR) is emerging as the leading cause of chronic rejection and allograft failure. Traditionally, the mechanisms of graft injury mediated by donor-specific antibodies beyond complement activation were not well appreciated. However, an evolving paradigm of Fc-independent antibody functions, along with clinical recognition of C4d-negative AMR, has increased awareness of the action of antibodies leading to endothelial activation and dysfunction.
INTRODUCTION
Antibody-mediated rejection (AMR) is an increasingly problematic entity in solid organ transplantation that leads to graft dysfunction and loss. AMR often occurs late (>1 year) after transplantation with an incidence of approximately 30% [1 & ], and was recently attributed to cause half of all renal allograft failures [2] . An understanding of how antibodies cause graft injury and promote acute and chronic rejection is critical for the management of sensitized recipients and improvement of therapeutics. Studies from our group and others have previously demonstrated that human leukocyte antigen (HLA) I antibodies act as agonists, inducing molecular aggregation of HLA class I molecules to trigger intracellular signaling pathways that are critical in the regulation of cell survival, proliferation, and migration in graft vascular cells (reviewed in [3] ).
CHARACTERISTICS OF ANTIBODY-MEDIATED REJECTION AND DRAWBACKS OF CURRENT HISTOLOGICAL CRITERIA
Consensus guidelines for the histological diagnosis of AMR center around circulating donor specific antibodies (DSA) vascular injury, microvascular changes, and complement (C4d) deposition. However, AMR criteria have in some cases proved inadequate because of the reliance on complement staining [1 & ,2], and, while C4d appears to be a specific marker in cardiac and renal transplantation, it is estimated that half of AMR events are missed because of the lack of sensitivity of C4d staining [4] . To date, no consensus AMR diagnostic criteria exist in lung and liver [5, 6] , because of controversy over the clinical significance of DSA in liver transplantation and a lack of specificity of C4d staining in lung allografts [5] [6] [7] [8] .
Recent efforts have aimed at discovery of superior histological indicators that can discriminate AMR from acute cellular rejection, infection, drug toxicity and stable graft function, and identify C4d-negative AMR. Extracellular matrix regulators matrix metalloproteinase-2 (MMP2) and TIMP metalloprotease inhibitor 1) were upregulated in renal biopsies during AMR [9] , which may play a role in fibrosis during chronic rejection. Several groups have recently reported that glomerulitis and peritubular capillaritis (microcirculation or microvascular inflammation) correlate with DSA and graft failure in renal transplants [10] [11] [12] . Moreover, activation of capillary endothelial cell signaling correlates closely with AMR severity, DSA, and microcirculation inflammation, and is a more sensitive AMR marker than C4d deposition [13 & ,14] in cardiac transplantation. A 'molecular phenotyping' approach, predominantly composed of endothelialassociated transcripts expressed in the renal allograft, could also identify C4d-negative AMR [15] . A new subclassification of AMR with vasculitis was recently proposed, which increased predictive value for renal allograft loss [16 && ]. Additionally, intravascular macrophages, identified by CD68 staining, appear to be a common feature of AMR [17] , and provide a more sensitive histological marker compared with C4d in cardiac allografts [18] . Intragraft macrophages also increase the risk of renal allograft dysfunction [11] , although macrophage staining is not currently included in the Banff criteria. Natural killer (NK) cells have also been implicated in antibody-mediated graft injury, particularly in late AMR [19] . These clinical results are paralleled by observations in experimental models, wherein depletion of NK cells ameliorated major histocompatibility complex class I (MHC I) antibody-induced chronic rejection in murine cardiac allografts [20 && ]. Taken together, these clinical observations highlight the central role of endothelial activation and innate immune infiltration in graft injury by donor-specific antibodies.
NEW TRENDS
There is a wealth of literature regarding the incidence and deleterious impact of donor-specific HLA antibodies, and this topic has been thoroughly reviewed elsewhere [21, 22] . ]. An emerging trend is the intriguing but little understood phenomenon of predominant DSA to HLA class II DQ locus (HLA-DQ) in lung [25] , cardiac [26] , renal [27] , and liver transplant recipients [28] , particularly during chronic rejection [28] . The possible pathogenic mechanisms of antibodies to HLA-DQ are not yet clear, although recipients tend to have worse outcome than when anti-DQ antibodies are absent [29 & ]. Interestingly, DQ mismatch increases the risk of de-novo DSA development [27] . It is yet unknown whether antibodies to KEY POINTS HLA antibodies may be preexisting or develop at any time after transplant; however, most de-novo antibodies form 6 months or later posttransplant. HLA I antibodies appear earlier, whereas HLA II antibodies (particularly anti-HLA-DQ antibodies) develop in the late posttransplant period.
HLA-DQ antibodies
Donor-specific HLA antibodies stimulate endothelial cell signaling, including rapid exocytosis of P-selectin and production of chemokines, leading to inflammatory activation and leukocyte recruitment.
Engagement of Fc receptors on monocytes by certain subclasses of HLA I antibodies enhances monocyte recruitment by activated endothelial cells.
It is yet unclear whether antibodies that fix complement in in-vitro deposition assays have definitive clinical relevance. However, activation of complement by HLA antibodies in experimental models triggers production of complement split products that boost T-cell-mediated alloimmune responses.
HLA-DQ are a marker of end-stage graft injury and/or nonadherence; whether they are increased in circulation due to low HLA-DQ expression in the graft; or whether they represent an independent pathogenic actor.
Non-HLA antibodies
There is a growing evidence to suggest that antibodies against non-HLA antigens may contribute to AMR in solid organ transplantation. Reports show that 10-23% of recipients are presensitized to non-HLA antigens [30, 31] , whereas 22% form non-HLA antibodies after transplant [32] . Endothelial reactive antibodies have been used clinically to identify cases of AMR [33] , and the nature of these targets is starting to be elucidated. Non-HLA antibodies are found in renal, lung, and cardiac transplant recipients, but the targets appear to be unique to each solid organ. A recent study revealed that endothelial-reactive antibodies may recognize nonpolymorphic and polymorphic antigens on the endothelial surface [34] . However, conflicting reports suggest either that non-HLA antibodies independently reduce graft outcome [35] [36] [37] or that they have no significant impact [38 & ]. The issue is complicated by the observations that autoantibodies can occur independently of or concurrently with donor-specific HLA and major histocompatibility complex class I related chain A (MICA) antibodies. In lung transplants, non-HLA antibodies against K-a tubulin and collagen are associated with rejection, but these antibodies were preceded by HLA DSA and persisted after elevated HLA antibody levels subsided [39] , suggesting that non-HLA antibodies are markers of alloimmune damage.
Anti-endothelial cell antibody subclasses are reportedly immunoglobulin G (IgG)2 and IgG4 predominant, which are noncomplement fixing, suggesting a complement-independent mechanism of action [30] . However, antibodies against vimentin, K-a tubulin, and collagen have been associated with C4d deposition on erythrocytes, suggesting they could contribute to classical complement activation [40] . It is also likely that the pathogenic potential of non-HLA antibodies depends upon the target. For example, antiangiotensin II type 1 receptor antibodies contribute to hypertension and vasculopathy in renal and cardiac transplantation [41] and increase the risk of graft failure [42] . In summary, the targets of antibodies to non-HLA endothelial proteins are only beginning to be identified, and, for the most part, their mechanism of action beyond Fc-mediated functions remain to be further elucidated.
THE MECHANISMS OF ANTIBODY-MEDIATED GRAFT INJURY
Antibody-mediated acute rejection is primarily driven by the effector functions of the Fc fragment of HLA antibodies, whereas experimental evidence indicates that the Fc-independent effects of antibodies promote chronic inflammation and proliferation.
The significance of complement IgG1 and IgG3 are efficient activators of the classical complement cascade, as well as high affinity ligands for Fc g receptors expressed on myeloid cells including macrophages and NK cells (reviewed in [43] ). In the recent years, new assays have been developed to characterize the functional deposition of complement components, including C1q, C3d, and C4d, by HLA antibody in solid phase assays or cell-based [44] [45] [46] . However, contradictory conclusions have been reached regarding the predictive significance of complement-fixing DSA detected by these assays [47,48 && ], and the results often do not correlate with lymphocytotoxicity [complement dependent cytotoxicity (CDC)-XM] results [46] . Moreover, despite the predominance of complement-fixing IgG1 DSA in recipients [28, 49 && ], only certain specificities exhibit cytotoxicity or C1q deposition. Antigen density or synergism of multiple low-level allele-specific antibodies may explain the differences (reviewed in [50] ). Additionally, complement fixation appears to be closely dependent upon antibody titer [51] and confounded by the presence of immunoglobulin M [52] . Indeed, poorer outcomes associated with complementfixing antibodies in some studies may be in fact reflective of high donor-specific antibody levels [48 && ]. Duquesnoy et al. [53] proposed the theory that complement fixation is a function of the epitope itself, which induces conformational changes in the antibody to confer binding to the C1 complex. Additionally, it is possible that differences in Fc glycan composition may lead to increased cytotoxicity of certain HLA DSA (reviewed in [54] ). Although interesting, experimental evidence addressing these putative mechanisms remains to be reported.
The utility of C4d staining has recently been questioned [16 && ], particularly late in transplantation [23 & ]. Antibody-mediated chronic injury does not always correlate with or require complement activation in clinical studies [55] or experimental models [20 && ]. Whereas HLA antibodies trigger complement-dependent cytotoxicity of target lymphocytes, endothelial cells -the primary target of antibody-mediated alloimmunity -are generally resistant to complement-mediated cell lysis in response to HLA antibodies. Despite evidence of terminal complement activation at the endothelial cell surface [44,56 && ], endothelial cells may upregulate cytoprotective factors and survival signaling to prevent HLA antibody-induced cytotoxicity [57, 58] . Therefore, the physiological relevance of complement-activating antibodies detected by C1q or C3d-fixing assays remains unclear, and the mechanisms of antibody-mediated graft injury in C4d-negative AMR have yet to be fully elucidated.
Complement-independent antibody-mediated endothelial and smooth muscle cell activation HLA antibodies also act as agonists to induce intracellular signaling in endothelial and smooth muscle cells. Notably, these effects are independent of the Fc fragment, and may therefore be elicited by any IgG subclass. HLA I antibodies promote focal adhesion kinase-dependent proliferation and migration of smooth muscle cells [59] , which may contribute to the neointimal changes seen in chronic rejection. Recent evidence has also implicated MMP2 and neutral sphingomyelinase-2 (nSMase2) in HLA I antibody-induced smooth muscle cell proliferation in vitro and in vivo [60] , which is interesting in light of clinical observations of increased intragraft expression of MMP2 during AMR [9] . Active MMP2 acts on nSMase2 to stimulate, among other effects, production of ceramide. Ceramide is itself a proinflammatory stimulus, and can be converted to sphingosine-1-phosphate (S1P), which is mitogenic through mitogen activated protein kinase/extracellular-signal regulated kinase (ERK) pathways [61] . In this study, the authors speculated that nSMase2 activation generates S1P, but as yet no evidence has linked HLA I antibodies with ceramide and/or S1P production. Further studies are needed in this novel area to dissect the proximal signaling leading to MMP2 and nSMase2 activation, to confirm the role of S1P in smooth muscle cell proliferation. If S1P is indeed produced in response to HLA I cross-linking, it would be of interest to examine other phenotypic changes triggered by this mediator, such as regulation of cell motility, control of barrier function, and modulation of endothelial inflammatory activation.
Cell proliferation and migration are dependent upon reorganization of the cytoskeleton. Recently, our group characterized HLA I-induced cytoskeletal rearrangement in greater detail, demonstrating that HLA I cross-linking activated Rho kinase, myosin light chain kinase, and ERK1/2 in a calciumindependent manner to stimulate stress fiber formation. This study also revealed a novel molecular association of ERK1/2 with mammalian target of rapamycin complex 2 (mTORC2), and showed that Rictor and ERK relocalize to the plasma membrane after HLA I antibody stimulation. These results suggest that ERK1/2 is a critical regulator of endothelial cytoskeletal changes, migration, and motility [62] .
In addition to cell motility, the intact cytoskeleton is required for activation of critical kinases downstream of HLA I cross-linking. Proteomic analysis demonstrated that HLA I cross-linking induced the association of many phosphorylated proteins, including eukaryotic initiation factor 4A1 (eIF4A1), with the actin cytoskeletal fraction [63 & ] eIF4A1 is a target of mTORC1 and is required for protein translation and cell proliferation. The cytoskeleton is actively involved in and required for translation, through spatial organization of the protein synthesis machinery, delivery of tRNAs to polysomes, and support of compartment-restricted localized translation of specific RNA [64] . Taken together, these studies highlight the central role of cytoskeleton in mediating the cell signaling process and raise fascinating questions regarding the functional link between the cytoskeleton and protein synthesis machinery in HLA I signaling.
Intracapillary macrophages are an important hallmark of AMR in cardiac allografts [17] , and macrophages are key immune mediators of graft injury. Endothelial cells actively regulate infiltration of leukocytes from the bloodstream into the tissue. Type 1 endothelial cell activation involves rapid and transient induction of adhesion molecules and chemoattractants, whereas type 2 activation requires protein synthesis resulting in chemokine and adhesion molecule expression over the course of hours or days. Emerging evidence indicates that HLA cross-linking can trigger both type 1 and type 2 endothelial cell activation, providing some insight into the mechanisms of macrophage recruitment to the allograft during HLA antibody-mediated injury. We and others reported that HLA I cross-linking by antibodies triggers rapid endothelial exocytosis (<30 min, type 1 activation) leading to cell surface presentation of the adhesion molecule P-selectin and release of von Willebrand Factor [65 & ,66] from aortic, venous, and microvascular endothelial cells [67] . This induction did not require the Fc portion of the antibody, suggesting that all IgG subclasses can elicit pathogenic effects by direct endothelial cell activation. P-selectin was indispensable for increased adhesion of monocytes in vitro and for accumulation of macrophages in murine cardiac allografts in vivo in response to MHC I antibodies [65 & ]. Interestingly, we observed that complement-fixing HLA I antibody dramatically augmented basal P-selectin-mediated monocyte adhesion through engagement of monocyte Fc g receptors (FcgRs) [67] , indicating that DSA subclasses that interact efficiently with FcgRs elicit enhanced recruitment of monocytes through dual activation of endothelium and monocytes.
In addition to early endothelial activation, HLA I antibodies induce late phase adhesion molecules and synthesis of chemoattractants and inflammatory cytokines that promote inflammation. For example, HLA I cross-linking activated the transcription factor cyclic adenosine monophosphate response element binding protein (CREB), which lead to increased adhesion molecule and chemokine expression by microvascular endothelium, and monocyte adhesion [68] . Similar studies found increased synthesis of cytokines and chemokines by endothelial cells from other vascular beds [69] upon exposure to HLA antibodies (Table 1 
CONCLUSION
In summary, vasculitis and microvascular inflammation have emerged as promising histological markers, underscoring the central role of endothelial injury in AMR. Experimental evidence suggests that HLA antibody-induced endothelial cell inflammatory activation may promote the microcirculation inflammation and innate immune infiltration characteristic of AMR. Moreover, Fc-mediated functions such as complement activation and engagement of Fc receptors act synergistically with endothelial activation to enhance inflammation and alloimmune damage. Many questions remain, including the physiological relevance of prevalent anti-DQ antibodies, non-HLA antibodies, and antibodies that fix complement in vitro; and the effects of HLA II antibodies on vascular cells.
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